Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)

The report reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects

The report assesses Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Arno Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Hutchison MediPharma Limited

ImmunoGen, Inc.

Immunomedics, Inc.

Incyte Corporation

Innate Pharma S.A.

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

LFB S.A.

Lymphocyte Activation Technologies, S.A.

Medicenna Therapeutics, Inc.

Millennium Pharmaceuticals Inc

MorphoSys AG

Novartis AG

Oncternal Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd.

Portola Pharmaceuticals, Inc.

Sanofi

Tragara Pharmaceuticals, Inc.

Verastem, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8

Therapeutics Development 9

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 9

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17

Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20

Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21

4SC AG 21

AbbVie Inc 22

Arno Therapeutics, Inc. 23

Astellas Pharma Inc. 24

Astex Pharmaceuticals Inc 25

Boehringer Ingelheim GmbH 26

Bristol-Myers Squibb Company 27

Celgene Corporation 28

Cellular Biomedicine Group, Inc. 29

F. Hoffmann-La Roche Ltd. 30

Gilead Sciences, Inc. 31

Hutchison MediPharma Limited 32

ImmunoGen, Inc. 33

Immunomedics, Inc. 34

Incyte Corporation 35

Innate Pharma S.A. 36

Juno Therapeutics Inc. 37

Karyopharm Therapeutics, Inc. 38

LFB S.A. 39

Lymphocyte Activation Technologies, S.A. 40

Medicenna Therapeutics, Inc. 41

Millennium Pharmaceuticals Inc 42

MorphoSys AG 43

Novartis AG 44

Oncternal Therapeutics, Inc. 45

Ono Pharmaceutical Co., Ltd. 46

Portola Pharmaceuticals, Inc. 47

Sanofi 48

Tragara Pharmaceuticals, Inc. 49

Verastem, Inc. 50

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Combination Products 52

Assessment by Target 53

Assessment by Mechanism of Action 56

Assessment by Route of Administration 59

Assessment by Molecule Type 61

Drug Profiles 63

(dezapelisib + itacitinib adipate) - Drug Profile 63

4SC-202 - Drug Profile 64

acalabrutinib - Drug Profile 66

ACP-319 - Drug Profile 69

afuresertib hydrochloride - Drug Profile 70

AGS-67E - Drug Profile 73

AR-42 - Drug Profile 75

AT-7519 - Drug Profile 77

atezolizumab - Drug Profile 80

BI-836826 - Drug Profile 94

BMS-986016 - Drug Profile 96

buparlisib hydrochloride - Drug Profile 98

CBM-C19.1 - Drug Profile 103

CBM-C20.1 - Drug Profile 104

CC-122 - Drug Profile 106

Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 108

Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 109

cerdulatinib - Drug Profile 110

duvelisib - Drug Profile 113

HMPL-523 - Drug Profile 123

idelalisib - Drug Profile 125

IMGN-529 - Drug Profile 133

IMMU-114 - Drug Profile 135

JCAR-014 - Drug Profile 137

JCAR-015 - Drug Profile 140

lirilumab - Drug Profile 144

MDNA-56 - Drug Profile 148

monalizumab - Drug Profile 149

MOR-208 - Drug Profile 152

nivolumab - Drug Profile 157

obinutuzumab - Drug Profile 183

PCAR-019 - Drug Profile 190

PCAR-119 - Drug Profile 191

pilaralisib - Drug Profile 192

S-055746 - Drug Profile 195

selinexor - Drug Profile 196

spebrutinib besylate - Drug Profile 215

TAK-659 - Drug Profile 217

TG-02 - Drug Profile 218

tisagenlecleucel-T - Drug Profile 221

ublituximab - Drug Profile 226

UC-961 - Drug Profile 233

ulocuplumab - Drug Profile 235

urelumab - Drug Profile 236

venetoclax - Drug Profile 238

Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 247

Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 249

Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 250

Featured News & Press Releases 250

Appendix 262

Methodology 262

Coverage 262

Secondary Research 262

Primary Research 262

Expert Panel Validation 262

Contact Us 262

Disclaimer 263

List of Tables

List of Tables

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016 12

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Development by Companies, H2 2016 (Contd..2) 22

Products under Investigation by Universities/Institutes, H2 2016 23

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by 4SC AG, H2 2016 24

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by AbbVie Inc, H2 2016 25

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Arno Therapeutics, Inc., H2 2016 26

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astellas Pharma Inc., H2 2016 27

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astex Pharmaceuticals Inc, H2 2016 28

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 29

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bristol-Myers Squibb Company, H2 2016 30

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Celgene Corporation, H2 2016 31

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cellular Biomedicine Group, Inc., H2 2016 32

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 33

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Gilead Sciences, Inc., H2 2016 34

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Hutchison MediPharma Limited, H2 2016 35

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by ImmunoGen, Inc., H2 2016 36

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Immunomedics, Inc., H2 2016 37

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Incyte Corporation, H2 2016 38

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Innate Pharma S.A., H2 2016 39

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Juno Therapeutics Inc., H2 2016 40

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 41

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by LFB S.A., H2 2016 42

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016 43

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Medicenna Therapeutics, Inc., H2 2016 44

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 45

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by MorphoSys AG, H2 2016 46

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Novartis AG, H2 2016 47

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Oncternal Therapeutics, Inc., H2 2016 48

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 49

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Portola Pharmaceuticals, Inc., H2 2016 50

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Sanofi, H2 2016 51

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Tragara Pharmaceuticals, Inc., H2 2016 52

Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline by Verastem, Inc., H2 2016 53

Assessment by Monotherapy Products, H2 2016 54

Assessment by Combination Products, H2 2016 55

Number of Products by Stage and Target, H2 2016 57

Number of Products by Stage and Mechanism of Action, H2 2016 60

Number of Products by Stage and Route of Administration, H2 2016 63

Number of Products by Stage and Molecule Type, H2 2016 65

Refractory Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H2 2016 250

Refractory Chronic Lymphocytic Leukemia (CLL) – Dormant Projects (Contd..1), H2 2016 251

Refractory Chronic Lymphocytic Leukemia (CLL) – Discontinued Products, H2 2016 252

List of Figures

List of Figures

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016 12

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Assessment by Monotherapy Products, H2 2016 54

Number of Products by Top 10 Targets, H2 2016 56

Number of Products by Stage and Top 10 Targets, H2 2016 56

Number of Products by Top 10 Mechanism of Actions, H2 2016 59

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 59

Number of Products by Routes of Administration, H2 2016 62

Number of Products by Stage and Routes of Administration, H2 2016 62

Number of Products by Molecule Types, H2 2016 64

Number of Products by Stage and Molecule Types, H2 2016 64

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports